#Myeloma Paper of the Day: Study of RAS/RAF finds 61% of plasma cell dyscrasia patients presented w/ mutations, lower frequencies in pre-symptomatic cases, different mutations vs. solid tumors, & some having mutations in different subclones: pubmed.ncbi.nlm.nih.gov/38643494/.

Imp manuscript from the Mayo group Saurabh Zanwar showing the outcomes of pts w/ suboptimal response to DaraVCd in NDAL. I have traditionally switched to BCL2 inhibition ASAP if t(11;14) but for the rest such a tricky spot! Hopeful for TCE in this popn

nature.com/articles/s4137…

#Myeloma Paper of the Day: Study of real world impact of bridging therapy prior to CAR T finds response showed no significant association with CRS, ICANS rates, or 3-month post-CAR-T response, and median PFS didn’t significantly differ based on response: pubmed.ncbi.nlm.nih.gov/38609386/.

IMF Research Milestone! #ODAC unanimously votes yes on #MRD testing as an accelerated endpoint in #clinicaltrials . A decade of effort by the IMF. Thank you, Dr. Durie and i2TEAMM for paving the way for faster #FDA approvals in #myeloma drug development. myeloma.org/node/10787

Huge win for #myeloma patients today! The ODAC committee approved MRD testing as an early endpoint for MM drugs in trials. This accelerates progress towards new treatments! Thank you all who participated Nikhil C. Munshi, MD C. Ola Landgren, M.D. International Myeloma Foundation + #mmsm myeloma.org/news-events/mu…

#Myeloma Paper of the Day: A preliminary investigation evaluating ChatGPT as an educational resource for patients with multiple myeloma concludes it has 95% accuracy rate in answering key questions: pubmed.ncbi.nlm.nih.gov/38602288/.

Thanks Robert Z. Orlowski for highlighting this brief correspondence on artificial intelligence, which is more common than you would think! #AI #mmsm Ludovic Saba Chakra Chaulagain MD FACP Jack Khouri Faiz Anwer MD Cleveland Clinic MD

It is an honor to collaborate with our colleagues Beth Faiman PhD Faiz Anwer MD Jack Khouri on this project from Cleveland Clinic Florida Maroone Cancer at Cleveland Clinic Florida Ludovic Saba

Thankful for this collaborative effort! Cleveland Clinic MD #CleClinicCancer

Impact of bridging therapy with Ide-cel for myeloma:U.S. Myeloma Immunotherapy Consortium. Blood Cancer Journal. Key takeaway: 'Less is more'; exercise caution with intensified/infusional Cy, if feasible. #myeloma #CAR -T
shorturl.at/eqyZ5

Multiple myeloma patients previously treated with T-cell redirection therapy have significantly low risk of developing CRS with teclistamab ⁦MSK Department of Medicine⁩ #mmsm ashpublications.org/bloodadvances/…

Congratulations to Dr. Matt Kalaycio Cleveland Clinic MD Cleveland Clinic - new chair of National Comprehensive Cancer Network (NCCN) board of directors John Suh Case Comp Cancer Ctr !

38 year old male with h/o residency

FDA Approves Cilta-Cel for R/R Multiple Myeloma Who Have Received at Least One Prior Line of Therapy and Are Refractory to Lenalidomide #mmsm onclive.com/view/fda-appro…

With these awesome people Vaishali Sanchorawala #WashingtonDC

Real-World Database Studies in Oncology: A Call for Standards in Journal of Clinical Oncology will give guidance on the conduct and reporting of RWD in JCO including quality standards
ascopubs.org/doi/full/10.12…

#Myeloma Paper of the Day: #Darzalex shows efficacy against warm auto-immune hemolytic anemia (AIHA;(ORR was 50%; median response duration of 5.5 months), and in cold AIHA (ORR was 57%, with ongoing response in 3/7 patients): pubmed.ncbi.nlm.nih.gov/38507742/.

Systemic Amyloidosis and Kidney Transplantation: An Update pubmed.ncbi.nlm.nih.gov/38490903/
BU Amyloidosis Center Ashish Verma

Where in my CV do I put that I got this orchid to bloom after 7 years of barrenness?

ODAC Casts 11 to 0 Vote in Favor of Cilta-Cel in R/R Multiple Myeloma cancernetwork.com/view/odac-cast…